Stenoparib, an inhibitor of cellular poly (ADP-ribose) polymerase (PARP), blocks replication of the SARS-CoV-2 human coronavirus in vitro.
N. E. Stone, S. A. Jaramillo, A. N. Jones, A. J. Vazquez, M. Martz, L. M. Versluis, M. O. Raniere, H. E. Nunnally, K. E. Zarn, R. Nottingham, J. W. Sahl, D. M. Wagner, S. Knudsen, E. W. Settles, P. S. Keim, C. T. French
This paper evaluates stenoparib, a PARP inhibitor, for antiviral activity against SARS-CoV-2 and other coronaviruses in vitro, showing dose-dependent suppression and potential synergy with remdesivir.
bioRxiv · Nov 12, 2020 · PreprintMicrobiology